Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

All thanks to three key catalysts. Tempus AI just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which includes $375 million in cash payments and $225 million ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI stock price has rebounded this year ... The TEM stock also jumped to $61 after the company completed its acquisition of Ambry Genetics. Its market cap has moved to over $9 billion ...

The company recently completed its acquisition of Ambry Genetics, providing Tempus AI with the ability to offer patients more comprehensive cancer screening with Ambry's hereditary cancer assay.

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

CHICAGO, February 03, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has ...

Tempus AI, Inc. (NASDAQ ... including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health ...